Clinical response · Patients with collagenous colitis
It is very uncertain whether mesalazine changes clinical response compared with mesalazine + cholestyramine (very low certainty).
1 finding from 1 review
Adverse events · Patients with collagenous colitis
It is very uncertain whether mesalazine changes adverse events compared with mesalazine + cholestyramine (very low certainty).
1 finding from 1 review
Clinical response · patients with maintenance of remission in lymphocytic colitis
Mesalazine showed no clear difference in clinical response compared with mesalazine + cholestyramine (low certainty).
1 finding from 1 review
Histological response · patients with maintenance of remission in lymphocytic colitis
Mesalazine showed no clear difference in histological response compared with mesalazine + cholestyramine (low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · people with active UC
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found